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OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for controlling chemotherapy-
induced neutropenia and to evaluate the non-inferiority of the test drug relative to the originator.
METHODS: This phase III non-inferiority study had a randomized, multicenter, and open-label design. The
patients were randomized at a ratio of 1:1 with a follow-up period of 6 weeks for each patient. In both study
arms, filgrastim was administered subcutaneously at a daily dose of 5 mg/kg body weight. The primary endpoint
was the rate of grade 4 neutropenia in the first treatment cycle. The secondary endpoints were the duration of
grade 4 neutropenia, the generation of anti-filgrastim antibodies, and the rates of adverse events, laboratory
abnormalities, febrile neutropenia, and neutropenia of any grade.
RESULTS: The primary efficacy analysis demonstrated the non-inferiority of the test drug compared with the
originator drug; the upper limit of the 90% confidence interval (CI) for the rate of neutropenia between the
two groups (12.61%) was lower than the established margin of non-inferiority. The two treatments were similar
with respect to the secondary endpoints and safety.
CONCLUSION: The efficacy and safety profile of the test drug were similar to those of the originator product
based on the rate of grade 4 neutropenia in the first treatment cycle. This study supports Anvisa’s approval of
the first biosimilar drug manufactured by the Brazilian industry (Fiprimas).
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’ INTRODUCTION
Neutropenia is one of the most common chemotherapy-
related adverse events, with a mortality rate of 10%, and it
increases the costs associated with cancer treatment (1,2).
Moreover, neutropenia is a severe limiting factor during
chemotherapy (3) and may lead to decreased dosages and
reduced treatment effectiveness (4,5), especially when chemo-
therapy is indicated for curative purposes, as is the case with
the adjuvant treatment of breast cancer (6).
There is a direct correlation between absolute neutrophil
count (ANC) and the risk of opportunistic infections in
cancer patients undergoing chemotherapy (3). Counts below
500 neutrophils/mm3 are associated with an increased risk of
infection or fever without the objective identification of
microorganisms. It is estimated that 25%–40% of patients
without previous treatment develop febrile neutropenia (7),
which is defined as an ANCo500/mm3 and an oral temp-
erature X38.2oC (8). This is categorized as grade 4 neutro-
penia on the 0–5 scale that is currently used for this adverse
event (9).
The risk of febrile neutropenia varies according to the specific
chemotherapy regimen (10). In patients with febrile neutrope-
nia, toxicity commonly occurs during the initial chemother-
apy cycles (11), reaching a maximum intensity between 7 and
14 days after initiating chemotherapy. This risk depends on
numerous other factors, including tumor type and patient
characteristics, such as age and performance status (1,5,12).DOI: 10.6061/clinics/2016(10)06
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The use of broad-spectrum antibiotics and hematopoietic
growth factors is currently considered effective against chemo-
therapy-induced toxicity (8,10,13,14).
Granulocyte colony-stimulating factor (G-CSF) is the most
commonly used hematopoietic growth factor for the pro-
phylaxis of febrile neutropenia. The G-CSF class of ther-
apeutic agents was developed by isolating, purifying, and
cloning this hematopoietic regulatory factor (15). The human
G-CSF gene was inserted into Escherichia coli using recombi-
nant DNA technology to produce Filgrastim, which has been
approved for clinical use since 1991 (16). Because G-CSF
receptors are expressed solely in precursor and mature myeloid
cells, the mechanism of action of filgrastim is selective; it
stimulates the proliferation, differentiation, and activation of
the neutrophil lineage, as well as shortens the neutrophil
maturation period.
Recently, a pegylated formulation of filgrastim was released
that reduced the renal clearance of the drug and increased
the terminal half-life compared with unpegylated filgrastim
(17). Pegylated filgrastim is administered in a single dose per
chemotherapy cycle, and its effectiveness in shortening the
duration of neutropenia is similar to that of daily filgrastim
(18,19). Therefore, both forms of filgrastim can be used for
the prophylaxis of febrile neutropenia.
Currently, the American Society of Clinical Oncology,
the European Organization for Research and Treatment of
Cancer, and the National Comprehensive Cancer Network
(14) recommend primary prophylaxis with G-CSF when the
expected rate of febrile neutropenia is X20%, regardless
of the impact of other factors (10,20). This expected rate of
febrile neutropenia at which primary prophylaxis with
G-CSF is recommended was recently reduced from the
previous rate of 40%.
Primary prophylaxis for febrile neutropenia can also be
given to patients at high risk of neutropenic complications,
even when the expected rate of febrile neutropenia iso20%.
The high-risk factors include age 465 years, low perfor-
mance status, cytopenia due to tumor-induced impairment
of the bone marrow, active infections, or open wounds.
Secondary prophylaxis is indicated for patients who pre-
viously experienced febrile neutropenia and for those whom
a lower chemotherapy dose or a prolonged interval between
chemotherapy cycles may be associated with worse overall
or disease-free survival (10).
A previous study of experimental filgrastim produced by
Eurofarma demonstrated comparability in terms of both
in vitro biological activity and in vivo (rodent) toxicology and
pharmacodynamics. A phase I, single-center, randomized
trial was undertaken to demonstrate the equivalence of
Eurofarma filgrastim and Roche filgrastim in terms of
pharmacokinetic characteristics. Eurofarma filgrastim was
well tolerated with no additional safety concerns compared
with Roche filgrastim. Eurofarma filgrastim is bioequivalent
to Roche filgrastim with regard to pharmacokinetics (21).
The aim of this study was to compare the efficacy and safety
of two filgrastim formulations for controlling chemotherapy-
induced neutropenia and to evaluate the non-inferiority of the
test drug in relation to the originator.
’ METHODS
This phase III, non-inferiority, randomized, open-label,
multicenter study compared two products containing
filgrastim: the test drug (Fiprimas, Eurofarma) and the
originator drug (Granulokines, Roche). The primary end-
point was the rate of grade 4 neutropenia in the first treat-
ment cycle (considering the lower ANC value). The secondary
endpoints included the rates of febrile neutropenia and
neutropenia of any grade, the duration of grade 4 neutro-
penia, the generation of anti-filgrastim antibodies, and the
frequency of adverse events and laboratory abnormalities.
This study was approved by the Research Ethics Com-
mittee of the participating institutions. All the participants
provided written informed consent before undergoing any
procedure in accordance with the Brazilian standards of
Good Clinical Practice and the Declaration of Helsinki.
The selected patients included those with breast cancer
stage II to IV; those with an indication for full-dose chemo-
therapy with one of the two eligible regimens (TAC regimen:
75 mg/m2 docetaxel, 50 mg/m2 doxorubicin, and 500 mg/m2
cyclophosphamide; or AT regimen: 75 mg/m2 docetaxel
and 60 mg/m2 doxorubicin); those with no more than one
previous chemotherapy regimen for metastatic disease with
a performance status of 0 or 1 on the Zubrod scale and ade-
quate organ function; and those agedX18 years who signed
the informed consent form.
The exclusion criteria were as follows: an expected require-
ment for prophylactic or therapeutic antibiotics, antifungals,
or antivirals in the first chemotherapy cycle; previous
radiotherapy involving the pelvis or radiation in any body
region in the 6 weeks prior to randomization; a history of
receiving a bone marrow transplant; other tumors or serious
comorbidities; recent participation (o12 months) in other
clinical studies involving medication of any type or in inter-
ventional studies; an intolerance or allergy to any component
of the filgrastim formulations evaluated in this study; and
pregnant or lactating women.
The main demographic characteristics of the patients in the
per-protocol (PP) and intention-to-treat (ITT) populations are
shown in Table 1 according to treatment arm.
After stratification according to clinical site and the previous
use of chemotherapy, the patients were randomized at a ratio
of 1:1 to receive filgrastim (Fiprimas or Granulokines); the
follow-up period for each patient was 6 weeks, except in cases
of death, withdrawal of consent, or loss to follow-up. In both
study arms, filgrastim was administered subcutaneously at a
daily dose of 5 mg/kg body weight until the ANC recovered
to X10,000/mm3 or until the 15th day of the chemotherapy
cycle (V14), whichever occurred first.
The patients were evaluated at the screening visit (SV),
at the randomization visit (RV, 7±3 days after the SV and
3±3 days before the first chemotherapy dose), and at daily
visits during treatment. Filgrastim was administered on
the odd visits (V1 to V13, such that V1 occurred on day 2
of the chemotherapy cycle), whereas on even visits (V2 to
V14), drug administration was accompanied by health and
safety assessments and laboratory tests. The final visit (FV)
occurred 3 weeks (±5 days) after the first day of chemo-
therapy.
Statistical analysis
To assess the non-inferiority of the test drug compared
with the originator drug, the 90% CI for the difference in the
rates of grade 4 neutropenia between the two groups was
initially calculated. Non-inferiority was defined as an absolute
value of the upper limit of the CI o15%. In an exploratory
manner, the 95% CI for the difference in the rate of grade 4
neutropenia between the two groups was also calculated.
587
CLINICS 2016;71(10):586-592 A biosimilar filgrastim study
Hegg R et al.
Continuous variables are presented as the variation (mini-
mum and maximum values), mean, standard deviation (SD),
median, and interquartile range (25th percentile [Q1] – 75th
percentile [Q3]). Categorical variables are described as
absolute and relative frequencies. The Kolmogorov-Smirnov
test with the Lilliefors correction was used to evaluate the
standard distribution of the outcome variables. The Lilliefors
correction was also used to adjust the estimated population
parameters (mean and variance or SD).
Continuous variables with a normal distribution were
compared using t-tests, whereas variables with a non-normal
distribution were compared using the nonparametric Mann-
Whitney test. Categorical variables were compared using the
chi-square test and the test for equality of proportions with
the continuity correction. In general, two-tailed significance
levels of 5% indicated significant differences between the
groups.
Sample size calculation
To calculate the sample size for the proposed non-
inferiority design, the historical incidence of grade 4 neutro-
penia after the first chemotherapy cycle was considered.
This value was between 73% and 83% in studies involving
the two eligible chemotherapy regimens. Considering a one-
tailed alpha of 5% and a statistical power of 80% for the
study to obtain a maximum absolute difference of 15% in the
rate of grade 4 neutropenia between the two groups, and
assuming that this rate would be 80% in the control group,
88 patients should be included in each study group. Assum-
ing a dropout rate of approximately 20%, 110 patients were
anticipated in each arm, for a total of 220 patients.
Study population
Between April 2011 and June 2012, 236 patients were
screened, of which 219 were randomized. The reasons for
randomization failure were withdrawal of consent (n=5) and
failure to meet the eligibility criteria (n=12); these failures
were due to inadequate organ function (n=8), the presence of
serious comorbidities (n=1), radiation within 6 weeks prior
to randomization (n=1), lack of an indication for chemother-
apy with one of the eligible regimens (n=1), and performance
status other than 0 or 1 on the Zubrod scale (n=1). Two
randomized female patients did not receive at least one dose
of the evaluated drugs; both patients discontinued the study
prematurely, one for loss to follow-up and the other for
withdrawal of consent. Of the 217 randomized patients who
received at least one dose of the study treatment, two
patients who had been randomized to receive the test drug
instead received the originator drug. Figure 1 shows the
flowchart of the study population according to treatment
group and the total number of patients in each group.
Of the 217 eligible patients who received treatment, all
belonged to the ITTand safety populations. Of these patients,
47 did not enter the PP population because they fulfilled
at least one of the following criteria: received commercial
filgrastim during the study period, were under medical
surveillance, and did not perform all the tests specified in the
study schedule (n=4); did not undergo an ANC evaluation at
the SV (n=1); did not have at least 3 ANC results between V2
and V14 (necessary for evaluating the primary endpoint,
n=1); or irregular administration of filgrastim (administra-
tion was discontinued before the ANC reached X10,000/
mm3 after reaching the nadir; n=41). Therefore, the ITT,
PP, and safety populations consisted of 217, 170 and 217
patients, respectively.
Four patients who received treatment, all from the origi-
nator drug group, prematurely discontinued the study due
to non-adherence to the protocol or treatment (n=1), with-
drawal of informed consent (n=1), use of medications not
allowed during the study period (n=1), and death (n=1).
’ RESULTS
The primary efficacy endpoint was determined by evaluat-
ing the non-inferiority of the test drug compared with the
originator drug with respect to the rate of grade 4 neutro-
penia in the PP population. This rate was defined as the ratio
of the number of patients with grade 4 neutropenia to the
total number of patients in each group during the first
chemotherapy cycle. Table 2 shows the percentage of
patients with grade 4 neutropenia in the first chemotherapy
cycle (between V2 and V14) stratified by treatment (test vs.
originator) and the comparison of the rates of grade 4
neutropenia between the two treatment arms. There results
was no significant difference (p=0.9971) in the rate of grade 4
neutropenia between the two groups in the first chemo-
therapy cycle.
The 90% CI for the difference in the rate of grade 4
neutropenia between the test and originator drugs in the
first chemotherapy cycle was between –12.67 and 12.61.
The CI included zero, which indicates the absence of a
significant difference in this rate between the two groups.
Table 1 - Demographic characteristics of the patients according to treatment arm in the ITT and PP populations.
ITT population (N=217) PP population (N=170)
Characteristic Test drug
(N=109)
Originator drug
(N=108)
Test drug
(N=86)
Originator drug
(N=84)
Age (years)
Mean ± SD 51.36±9.85 49.04±11.24 50.19±9.94 49.73±11.49
Range 30.11–76.39 22.30–78.10 30.11–76.39 22.30–78.10
Median 52.17 48.86 50.71 48.86
(44.94–58.09) (42.81–55.58) (42.91–57.19) (43.44–59.03)
Ethnicity
Caucasian 67 (61.5) 65 (60.2) 46 (53.5) 45 (53.6)
Black 13 (11.9) 13 (12.0) 11 (12.8) 9 (10.7)
Asian 3 (2.7) 2 (1.9) 3 (3.5) 2 (2.4)
Mixed 26 (23.9) 28 (25.9) 26 (30.2) 28 (33.3)
ITT: intention to treat; PP: per-protocol; SD: standard deviation. Mixed ethnicity included patients who marked ‘‘others’’ on the CRF. Age was calculated as
the difference between the date of birth and the screening visit (SV) date.
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To demonstrate the non-inferiority of the test drug compared
with the originator drug, the upper limit of the 90% CI for
the difference in the rate of neutropenia in the first cycle
should be smaller than the margin of non-inferiority (M),
which was set at an absolute value of 15%. Figure 2 presents
the results in graphical form; the upper limit of the CI
(12.61%) was below the M of 15% that was set during the
sample size calculation. This analysis indicated the non-
inferiority of the test drug in relation to the originator drug.
In addition to the 90% CI, the 95% CI for the difference in
the average rate of grade 4 neutropenia in the first cycle was
also calculated in an exploratory manner. This interval varied
between –15.06 and 15.00 and also included zero, demon-
strating the lack of a significant difference between the two
groups.
With regard to the secondary endpoint, the number of
patients with grade 4 neutropenia in the two groups in the
ITT population was 56 (51.4%) for the test drug and
59 (54.6%) for the originator drug. The comparison of these
rates indicated no significant difference between the two
groups (p=0.6311), although the rate was slightly lower for
the test drug than for the originator drug.
The rate of febrile neutropenia was defined as the ratio
of the number of patients with febrile neutropenia to the
total number of patients in each study group; only a single
episode of febrile neutropenia during the study period was
considered for each patient. The analysis of the PP popula-
tion indicated rates of 3.49% and 2.38% in the test and
originator drug groups, respectively; these rates were not
significantly different (p=0.669). In the ITT population, the
rates of febrile neutropenia were 3.7% and 2.8% for the test
and originator drugs, respectively; again, these rates were
not significantly different (p=0.710).
The rate of neutropenia of any grade was defined as the
ratio of the number of patients with neutropenia of any
grade (1 to 5) to the total number of patients in each group;
a single episode of neutropenia at its worst grade in the
evaluated cycle was considered for each patient. The number
of patients with neutropenia in the ITT population was
99 (90.8%) for the test drug and 93 (86.1%) for the originator
drug; there was no significant difference between the treat-
ment arms regarding this variable (p=0.2768).
Table 3 lists the results for the grade of neutropenia,
considering the worst grade for each patient in the ITT
population between visits V2 and V14. The comparison
between treatment groups using the chi-square test indicated
no significant difference.
The duration of grade 4 neutropenia in the two treatment
groups was estimated as the difference in days between the
date of the onset of grade 4 neutropenia and the response
‘‘Yes’’ to the question regarding changes in the grade of
neutropenia during the even visits. Because the evaluation
was not conducted daily, the duration categories considered
for this analysis were ‘‘within 2 days’’ and ‘‘3 to 4 days’’.
In the PP population, the number of patients with grade 4
neutropenia that lasted o2 days and 2–4 days was 39 (88.6%)
and 5 (11.4%), respectively, in the test drug group and
40 (95.2%) and 2 (4.8%), respectively, in the originator drug
group. In the ITT population, these numbers were 41 (89.1%)
and 5 (10.9%) in the test drug group and 39 (92.9%) and 3 [7.15]
in the originator drug group. The chi-square test indicated no
significant differences in the duration of neutropenia between
the two treatments in the two populations (PP, p=0.2631; ITT,
p=0.5436).
In addition, the neutrophil count was assessed at each visit
between the first and tenth days of study participation, and
Figure 1 - Flowchart of study population (CONSORT Diagram).
Table 2 - Rate of grade 4 neutropenia in the two treatment
groups in the PP population (N=170).
Grade 4 neutropenia Test drug
(N=86)
Originator
drug
(N=84)
p*
No 42 (48.84%) 41 (48.81%) 0.9971
Yes 44 (51.16%) 43 (51.19%)
(*) Test for equality of proportions with the continuity correction to
compare the rate of grade 4 neutropenia between the two treatment
groups.
Figure 2 - Primary analysis of efficacy in the PP population (test
drug versus originator drug; n=170).
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the data indicated that this value changed every other day.
For each visit, a neutrophil recovery curve was generated
considering the difference between the geometric mean
neutrophil count in each group (Figure 3). The vast majority
of patients received at least 9 daily filgrastim injections. The
recovery curves fully overlapped.
The generation of anti-filgrastim antibodies was assessed
by calculating the percentage of positive results (in the
confirmatory test) for IgA, IgG, and IgM at the SV and V8
in the safety population. In the characterization phase, the
samples with a positive result in the screening stage were
analyzed; in the confirmation phase, the samples positive
for any Ig in the characterization phase were analyzed.
Patients with samples from a single visit were not included.
The results indicated no significant difference in antibody
production between the treatment groups.
Safety results
In the safety population, 206 patients had mild-to-moderate
adverse events during the study period: 101 in the test drug arm
and 105 in the originator drug arm. The cases of neutropenia
were not considered adverse events because neutropenia was a
study endpoint and was therefore analyzed separately in the
efficacy analyses.
The most common adverse events in the two groups were
nausea (n=133; 61.3%), diarrhea (n=89; 41.0%), leukopenia
(n=50; 23.0%), vomiting (n=49; 22.6%), and asthenia (n=48;
22.1%). For events that occurred in both groups, the relative
difference between groups in the number of patients with at
least one occurrence of that event was evaluated. Hypothesis
tests for equality of proportions were conducted only for
events with a relative difference ofX10% between the groups.
Table 3 - Rate of neutropenia considering the worst grade for
each patient per treatment cycle in the ITT population (N=217).
Grade of neutropenia Test drug
(N=109)
Originator drug
(N=108)
p*
0 10 (9.2%) 15 (13.9%) 0.5886
1 2 (1.8%) 3 (2.8%)
2 14 (12.8%) 12 (11.1%)
3 27 (24.8%) 19 (17.6%)
4 56 (51.44%) 59 (54.6%)
(*) Chi-square test. For each patient, the worst grade of neutropenia
observed during the study period was considered.
ITT: intention to treat; PP: per-protocol
Figure 3 - Geometric mean neutrophil count at each visit, with 90% CIs and p-values identified at each study visit.
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There were no significant differences in the frequencies of
these adverse events between the groups.
Among the reported adverse events, 14 were considered
strongly correlated with the study drug (11 in the test drug
group and 14 in the originator drug group), 39 were con-
sidered possibly correlated with the study drug (26 in the test
drug group and 13 in the originator drug group), and
15 were considered most likely correlated with the study
medication (8 in the test drug group and 7 in the originator
drug group).
In the safety population (n=217), nine patients had serious
adverse events: three in the test drug arm (three records) and
six in the originator drug arm (nine records). All the reported
serious adverse events were considered clearly uncorrelated
with the study drug.
There was one reported death during the study. In the
database, this patient had documented abdominal pain and
vomiting as serious adverse events; however, these events
were considered uncorrelated with the study drugs.
’ DISCUSSION
This study compared two filgrastim formulations to eval-
uate the non-inferiority of a test drug relative to an originator
drug in the prevention and control of neutropenia associated
with the TAC and AT chemotherapy regimens. The primary
efficacy analysis of the primary endpoint in the PP popula-
tion demonstrated the non-inferiority of the test drug com-
pared with the originator drug; the upper limit of the 90% CI
for the difference between groups in the rate of grade 4
neutropenia in the first treatment cycle (test drug–originator
drug=12.61%) was lower than the absolute value of the pre-
established M (15%).
Notably, the incidence of grade 4 neutropenia in both
groups was lower than that used in the sample size calcula-
tion, most likely because blood counts were analyzed every
two days. Consequently, an exploratory analysis was con-
ducted using the 95% CI, and the result of this analysis
corroborated the primary analysis. The latter analysis was
broader and therefore more conservative, and its upper limit
coincided with the adopted margin. Although these results
are considered borderline with respect to demonstrating non-
inferiority, the fact that the 95% CI did not exceed the M is
further evidence in favor of the test drug.
It was not possible to demonstrate the superiority of the
test drug because no significant differences were observed
between the two formulations when the rates of grade 4
neutropenia in the first cycle were compared using the test
for equality of proportions with the continuity correction
(p=0.9971). The other comparative analyses revealed no
significant differences between the two formulations in the
other efficacy variables or in the toxicity profile.
In general, for the efficacy variables, the two drugs perfor-
med similarly with respect to the primary endpoint (rate of
grade 4 neutropenia in the first treatment cycle) and to the sec-
ondary endpoints (rate of febrile neutropenia and duration of
grade 4 neutropenia) evaluated in the PP and ITT populations.
Randomized trials have demonstrated the benefit of pro-
phylactic filgrastim for the treatment of cytotoxic chemother-
apy-induced neutropenia based on reductions in the following
criteria: rate of febrile neutropenia; duration of grade 4 neu-
tropenia; depth of the neutrophil nadir; number of hospi-
talizations; and rate of antibiotic use. Chemotherapy cycles of
doxorubicin followed by docetaxel are known to be associated
with a high incidence of hematological toxicity (rate of febrile
neutropenia: 33%) (22).
Despite a similar patient cohort in terms of median age
and treatment regimens, the rate of febrile neutropenia
among the patients in our population was almost half that
reported in pivotal studies. The reasons for this observation
are not evident, but there are numerous plausible explana-
tions, including fundamental differences in the patient
population, supportive care, and other unmeasured factors.
In our study, the women were chemotherapy naïve, with
less vulnerable bone marrow, and more responsive than
chemotherapy-pretreated patients. In contrast, 20% of the
patients in previously published studies had received prior
chemotherapy, a known risk factor for severe neutropenia.
Nevertheless, there was no significant difference between the
groups in our study (23,24).
With regard to safety, there were certain numerical dif-
ferences between the groups in some of the analyses. How-
ever, there was no apparent pattern that indicated which
treatment was less toxic. During the study period, there was
one recorded death in the originator drug group. There was
no significant difference in the frequency of adverse events
between the two treatment groups. In addition, although no
hypothesis tests were performed, our descriptive analyses
suggested that the groups were similar with respect to
changes in the measured laboratory parameters.
The efficacy of the test drug was similar to that of the
originator drug with respect to non-inferiority in the rate of
grade 4 neutropenia during the first chemotherapy cycle.
There were no significant differences in the other efficacy and
safety endpoints between the groups.
This study supports Anvisa’s approval of the first biosimilar
drug manufactured by the Brazilian industry (Fiprimas).
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